SCHEMBL145169

SCHEMBL145169

COC(=O)c1cc(Br)nc2c1[nH]c1cc(Cl)ccc12

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 2/20 0.51
MAP2K4 P45985 1/20 0.43
JAK2 O60674 1/20 0.42
CHEK1 O14757 1/20 0.41
ABL1 P00519 1/20 0.41
MAT2A P31153 1/20 0.40
RXFP1 Q9HBX9 1/20 0.39
MPL P40238 1/20 0.39
PTGES O14684 1/20 0.39
PRMT5 O14744 1/20 0.39
WDR77 Q9BQA1 1/20 0.39
KDM4E B2RXH2 1/20 0.39
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
MAPK1 P28482 1/20 0.39
BLM P54132 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL145786 0.87 JAK2 (0.43) NR4A2JAK2CHEK1MPLKDM4E
SCHEMBL141121 0.86 JAK2 (0.42) NR4A2JAK2MPLPRMT5WDR77
SCHEMBL138263 0.86 JAK2 (0.57) NR4A2JAK2KDM4EMEN1LMNA
SCHEMBL137418 0.84 JAK2 (0.41) NR4A2JAK2MPLKDM4EMEN1
SCHEMBL145348 0.82 PRMT5 (0.42) JAK2PRMT5WDR77MEN1LMNA
SCHEMBL141841 0.81 ALDH1A1 (0.40) JAK2KDM4EMEN1LMNAHPGD
SCHEMBL142806 0.81 DYRK1A (0.44) JAK2MPLKDM4EMEN1LMNA
SCHEMBL141886 0.79 JAK2 (0.55) JAK2KDM4EMEN1KMT2A
SCHEMBL142902 0.79 JAK2 (0.55) JAK2RXFP1MEN1KMT2A
SCHEMBL145515 0.78 MAOA (0.49) JAK2CHEK1KDM4ECYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 NR4A2 2585/4885MAP2K4 333/4885JAK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.